Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J. Gollob
Kym-001, a First-In-Class Oral Irak4 Protein Degrader, Induces Tumor Regression in Xenograft Models of Myd88-Mutant Abc DLBCL Alone and in Combination With BTK Inhibition
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Combination of Irak4 (Ca-4948) and BTK (Vecabrutinib) Inhibitors Show Superior Efficacy in Preclinical Models of Abc DLBCL Tumors Containing Myd88 -L265p Mutations
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Combination PI3K/MEK Inhibition Promotes Tumor Apoptosis and Regression in PIK3CA Wild-Type, KRAS Mutant Colorectal Cancer
Cancer Letters
Cancer Research
Oncology
Copanlisib in Combination With Anti-Pd-1 Induces Regression in Animal Tumor Models Insensitive or Resistant to the Monotherapies of Pi3k and Checkpoint Inhibitors
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Activity of Oral Atovaquone Alone and in Combination With Antimony in Experimental Visceral Leishmaniasis.
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models
Clinical Cancer Research
Cancer Research
Oncology
Effect of Erythropoietin on Human Tumor Growth in Xenograft Models
Molecular Medicine Reports
Oncology
Genetics
Molecular Biology
Biochemistry
Cancer Research
Molecular Medicine
Coping With Unbalanced Class Data Sets in Oral Absorption Models
Journal of Chemical Information and Modeling
Computer Science Applications
Chemistry
Chemical Engineering
Library
Information Sciences
Intratumoral G100, a TLR4 Agonist, Induces Anti-Tumor Immune Responses and Tumor Regression in Patients With Merkel Cell Carcinoma
Clinical Cancer Research
Cancer Research
Oncology
Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination With Vorinostat in KRAS-Mutant Colorectal Cancer Models
Clinical Cancer Research
Cancer Research
Oncology
